Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

• Published in: Zhongguo fei ai za zhi Vol. 27; no. 2; pp. 81 - 87
• Main Author: Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association; Chinese Antituberculosis Association 20.02.2024
• Subjects: anti-angiogenic drugs; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Consensus; expert consensus; Humans; Immunotherapy; lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mutation; negative driver gene mutations; Immunotherapy; Negative driver gene mutations; Anti-angiogenic drugs; Expert consensus; Lung neoplasms
• ISSN: 1999-6187; 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2024.102.10

For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients. At present, the first-line treatment can choose chemotherapy, anti-angiogenic drugs or immunotherapy. Although the initial treatment can achieve a certain clinical curative effect, disease progression or treatment failure is eventually unavoidable. The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically. An expert panel of respiratory medicine, pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations, aiming to provide guidances for Chinese clinicians in choosing second-line treatment for NSCLC pat